country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184926

Copy Link Print Information

PEG9MA10-PAB10-GalMA10

PEG9MA10-PAB10-GalMA10 is a CD147 LYTAC degrader. PEG9MA10-PAB10-GalMA10 binds to the asialoglycoprotein receptor (ASGPR) via its galactose methacrylate domain, mediating its uptake by hepatoma cells. PEG9MA10-PAB10-GalMA10 induces lysosome-dependent degradation of CD147, resulting in concurrent loss of associated MCT1 and MCT4. PEG9MA10-PAB10-GalMA10 reduces extracellular lactate levels, increases intracellular lactate accumulation, inhibits glycolytic activity, and enhances mitochondrial respiratory capacity. PEG9MA10-PAB10-GalMA10 decreases the secretion of MMP-2 and MMP-9, and upregulates the expression of E-cadherin. PEG9MA10-PAB10-GalMA10 exhibits anti-tumor efficacy in hepatoma models. PEG9MA10-PAB10-GalMA10 can be used for research on liver cancer (hepatocellular carcinoma).

For research use only. We do not sell to patients.

Formula: C₆₉₀H₁₀₅₆N₂₀O₂₇₃S₃
Molecular Weight:14095.93

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PEG9MA10-PAB10-GalMA10 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

MCT1

MCT4

MMP-2

MMP-9

All Monocarboxylate Transporter Isoforms :

All MMP Isoforms :

In Vitro

PEG9MA10-PAB10-GalMA10 (10-40 μM; 48 h) induces dose-dependent degradation of CD147 in HepG2 cells, and its level decreases to 49% of that in the control group after treatment with 40 μM for 48 h^[1].
PEG9MA10-PAB10-GalMA10 (5-20 μM; 48 h) induces dose-dependent degradation of CD147 in H22 cells, with its level decreasing to 39% of that in the control group after treatment with 20 μM for 48 h^[1].
PEG9MA10-PAB10-GalMA10 (20 μM) promotes lysosomal colocalization and degradation of CD147, MCT1 and MCT4 in Hepa1-6 cells^[1].
PEG9MA10-PAB10-GalMA10 increases intracellular lactate levels and decreases extracellular lactate levels in Hepa1-6 cells under both normoxic and hypoxic conditions, indicating impaired lactate efflux^[1].
PEG9MA10-PAB10-GalMA10 inhibits glycolytic activity (reduces maximal ECAR) and enhances mitochondrial respiratory capacity (increases maximal OCR) in Hepa1-6 cells^[1].
PEG9MA10-PAB10-GalMA10 (12-48 h) significantly inhibits the migration of Hepa1-6 cells in scratch wound healing assays^[1].
PEG9MA10-PAB10-GalMA10 reduces the secretion of MMP-2 and MMP-9 in Hepa1-6 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HepG2 human hepatocellular carcinoma cells
Concentration:

0, 10, 20, 40 μM
Incubation Time:

48 h
Result:

Reduced CD147 levels to 97%, 74%, and 49% of control at 10, 20, 40 μM after 48 h, respectively.

Western Blot Analysis^[1]

Cell Line:

H22 murine liver cancer cells
Concentration:

0, 5, 20 μM
Incubation Time:

48 h
Result:

Reduced CD147 levels to 89% and 39% of control at 5, 20 μM after 48 h, respectively.

In Vivo

PEG9MA10-PAB10-GalMA10 (40 mg/kg; administered intratracheally; given 4 times on days 0, 3, 6, and 9) inhibits subcutaneous H22 tumor growth and prolongs survival in female BALB/c mice via selective degradation of CD147 in tumor cells and reduction of intratumoral lactic acid levels^[1].
PEG9MA10-PAB10-GalMA10 (40 mg/kg; administered via intratracheal injection; 4 doses given on days 0, 3, 6, and 9) potently inhibits the growth of subcutaneous Hepa1-6-GFP tumors in female C57BL/6 mice via selective degradation of CD147 in tumor cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (female, 6-8 weeks old, subcutaneous injection of 2×10⁶ H22 cells)^[1]
Dosage:

40 mg/kg
Administration:

i.t.; 4 doses on days 0, 3, 6, 9
Result:

Suppressed tumour growth compared to controls.
Prolonged survival compared to controls.
Reduced intra-tumoural lactate levels.
Selectively degraded CD147 in CD45^- tumour cells (no effect on CD45⁺ immune cells).
Showed no significant body weight loss.

Animal Model:

C57BL/6 (female, 6-8 weeks old, subcutaneous injection of 2×10⁶ Hepa1-6-GFP cells)^[1]
Dosage:

40 mg/kg
Administration:

i.t.; 4 doses on days 0, 3, 6, 9
Result:

Suppressed tumour growth, with reduced tumour volume compared to controls.
Showed no significant body weight loss.
Selectively degraded CD147 in CD45^- GFP⁺ tumour cells (no effect on CD45⁺ GFP^- immune/stromal cells).

Chemical Information

Molecular Weight 14095.93
Formula C₆₉₀H₁₀₅₆N₂₀O₂₇₃S₃
SMILES

CCCCCCCCCCCCSC(SC(C(NC1=CC=C(O[C@H](O2)[C@H](O)[C@@H](O)[C@@H](O)[C@H]2CO)C=C1)=O)(C)CC(C(NC3=CC=C(O[C@H](O4)[C@H](O)[C@@H](O)[C@@H](O)[C@H]4CO)C=C3)=O)(C)CC(C(NC5=CC=C(O[C@H](O6)[C@H](O)[C@@H](O)[C@@H](O)[C@H]6CO)C=C5)=O)(C)CC(C(NC7=CC=C(O[C@H](O8)[C@H](O)[C@@H](O)[C@@H](O)[C@H]8CO)C=C7)=O)(C)CC(C(NC9=CC=C(O[C@H](O%10)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%10CO)C=C9)=O)(C)CC(C(NC%11=CC=C(O[C@H](O%12)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%12CO)C=C%11)=O)(C)CC(C(NC%13=CC=C(O[C@H](O%14)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%14CO)C=C%13)=O)(C)CC(C(NC%15=CC=C(O[C@H](O%16)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%16CO)C=C%15)=O)(C)CC(C(NC%17=CC=C(O[C@H](O%18)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%18CO)C=C%17)=O)(C)CC(C(NC%19=CC=C(O[C@H](O%20)[C@H](O)[C@@H](O)[C@@H](O)[C@H]%20CO)C=C%19)=O)(C)CC(CC(CC(CC(CC(CC(CC(CC(CC(C(OCCNC(/C(C)=C/C=C/C(C)(OC%21=O)C(C%22(CC%23)OC(C)=O)CCC%21%22CC=C%23C(OC)=O)=O)=O)(CC(CC(CC(CC(CC(CC(CC(CC(CC(CC(CC(C#N)(CCC(O)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)(C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%24=O)C(C%25(CC%26)OC(C)=O)CCC%24%25CC=C%26C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%27=O)C(C%28(CC%29)OC(C)=O)CCC%27%28CC=C%29C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%30=O)C(C%31(CC%32)OC(C)=O)CCC%30%31CC=C%32C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%33=O)C(C%34(CC%35)OC(C)=O)CCC%33%34CC=C%35C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%36=O)C(C%37(CC%38)OC(C)=O)CCC%36%37CC=C%38C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%39=O)C(C%40(CC%41)OC(C)=O)CCC%39%40CC=C%41C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%42=O)C(C%43(CC%44)OC(C)=O)CCC%42%43CC=C%44C(OC)=O)=O)=O)C)(C(OCCNC(/C(C)=C/C=C/C(C)(OC%45=O)C(C%46(CC%47)OC(C)=O)CCC%45%46CC=C%47C(OC)=O)=O)=O)C)=S
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Du J, et al. Nano-enabled spatially selective protein degradation modulates lactate metabolism to potentiate antitumor immunity in liver cancer. Nature nanotechnology. 2026 Jul;21(7):1036-1047. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

PEG9MA10-PAB10-GalMA10

All Monocarboxylate Transporter Isoforms

All MMP Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

PEG9MA10-PAB10-GalMA10 Related Classifications

HY-184926 Related Classifications